Drug Trial Radar · NCT04612413
A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients
Last checked: Nov 19, 2026Latest source record: Aug 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
148
Actual
Start
Nov 30, 2020
Primary completion
Jan 12, 2024
Study completion Dec 16, 2024
Sponsor
- Lead sponsor
- Enlivex Therapeutics Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 3, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2, Multi-Center, Randomized, Placebo-Controlled, Dose-Finding Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients
Conditions
- Sepsis
- Community-acquired Pneumonia
- Urinary Tract Infections
- Cholecystitis, Acute
- Cholangitis Acute
- Intraabdominal Infections
Interventions
Allocetra-OTSDrug
Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state and suspended in a solution containing DMSO.
PlaceboOther
Solution containing all excipients except for the Allocetra-OTS cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy: Change from baseline in SOFA scoreTime frame: 28 days
- Safety: Number and severity of AEs and SAEsTime frame: 28 days
Locations
31 sites in 5 countries. Site status is shown where the registry gives one.
Clinique Saint-Pierre
Brussels, Belgium
Saint-Luc Hospital University
Brussels, Belgium
CHU de Charleroi
Charleroi, Belgium
Ziekenhuis Oost-Limburg
Genk, Belgium
CHU d'Angers
Angers, France
Vendee Departmental Hospital Center
La Roche-sur-Yon, France
University Hospital of Limoges
Limoges, France
CHU de Montpellier
Montpellier, France
CHU de Nantes
Nantes, France
Bretonneau Hospital
Paris, France
Centre Hospitalier Victor Dupouy
Paris, France
Reims University Hospital Robert Debre
Reims, France
CHU de Rennes
Rennes, France
Strasbourg University Hospital
Strasbourg, France
Soroka Medical Center
Beersheba, Israel
Hillel Yaffe Medical Center
Hadera, Israel
Bnai Zion Medical Center
Haifa, Israel
Hadassah Ein Kerem Medical Center
Jerusalem, Israel
Beilinson Medical Center
Petah Tikva, Israel
Ziv Medical Center
Safed, Israel
Poriya Medical Center
Tiberias, Israel
Canisius Wilhelmina Hospital
Nijmegen, Netherlands
Radboud UMC
Nijmegen, Netherlands
Clinic Barcelona University Hospital
Barcelona, Spain
University Hospital Sagrat Cor
Barcelona, Spain
Vall d'Hebron
Barcelona, Spain
Getafe University Hospital
Getafe, Spain
Dr. Josep Trueta University Hospital
Girona, Spain
University Hospital Arnau de Vilanova of Lleida
Lleida, Spain
General University Hospital Gregorio Maranon
Madrid, Spain
University Hospital Joan XXIII of Tarragona
Tarragona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.